Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16772 studies found for:    Open Studies | "Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Conditions: Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Digestive System Neoplasms;   Endocrine Gland Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Lung Diseases;   Breast Diseases;   Renal Neoplasm;   Solid Tumors
Interventions: Drug: Entinostat;   Drug: Pembrolizumab
22 Recruiting Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Conditions: Breast Cancer;   Ovarian Epithelial Cancer Recurrent;   Sarcoma;   Non-small Cell Lung Cancer;   Carcinoma, Transitional Cell;   Prostate Cancer;   Prostatic Neoplasms
Intervention: Drug: Mifepristone and Eribulin in combination
23 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132
24 Not yet recruiting Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
Conditions: Hepatic Neoplasms;   Biliary Tract Neoplasms;   Pancreatic Neoplasms
Interventions: Behavioral: Perioperative rehabilitation program;   Behavioral: Conventional
25 Recruiting Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Conditions: Malignant Solid Tumour;   Carcinoma, Non-Small-Cell Lung;   Stomach Neoplasms;   Urothelial Carcinoma;   Endometrial Neoplasms;   Multiple Myeloma;   MPN;   Breast Cancer;   Cholangiocarcinoma
Interventions: Drug: INCB054828;   Drug: Gemcitabine+Cisplatin;   Drug: Pembrolizumab;   Drug: Docetaxel
26 Recruiting Early Detection of Pancreatic Cystic Neoplasms
Conditions: Pancreatic Cysts;   Intraductal Papillary Mucinous Neoplasm;   Pancreatic Mucinous-Cystic Neoplasm;   Cystic, Mucinous and/or Serous Neoplasm;   Solid Pseudopapillary Tumour of the Pancreas
Intervention:
27 Recruiting Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Conditions: Germ Cell Neoplasms;   Testicular Neoplasms;   Non Seminomatous Germ Cell Tumors;   Mediastinal Neoplasms;   Genital Neoplasms, Male;   Genital Neoplasms, Female;   Ovarian Neoplasms
Intervention: Drug: Pembrolizumab
28 Unknown  Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Liver Neoplasms
Interventions: Drug: 5-FU and oxaliplatin;   Procedure: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
29 Recruiting Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Conditions: Small Cell Lung Carcinoma;   Carcinoma, Squamous Cell of Head and Neck;   Stomach Neoplasms;   Triple Negative Breast Neoplasms;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Esophagogastric Junction Neoplasms
Interventions: Drug: paclitaxel + carboplatin;   Drug: carboplatin + etoposide;   Drug: gemcitabine + carboplatin;   Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin;   Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);   Biological: durvalumab;   Biological: tremelimumab
30 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
31 Recruiting Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
32 Recruiting Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
Conditions: AIDS-Related Non-Hodgkin Lymphoma;   Classical Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Malignant Neoplasm;   Recurrent Melanoma of the Skin;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Non-Small Cell Lung Carcinoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm;   Stage IIIA Hepatocellular Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Hepatocellular Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Hepatocellular Carcinoma;   Stage IIIC Skin Melanoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Skin Melanoma;   Stage IVA Hepatocellular Carcinoma;   Stage IVB Hepatocellular Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
33 Recruiting Efficacy of a Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively
Conditions: Breast Neoplasms;   Lung Neoplasms;   Colorectal Neoplasms;   Stomach Neoplasms
Interventions: Behavioral: Online health management program;   Behavioral: Health coaching;   Behavioral: Workshop;   Behavioral: Standard health educational booklet
34 Recruiting Precise Treatment in Hepatobiliary Cancers (PTHBC)
Conditions: Liver Neoplasms;   Biliary Tract Neoplasms;   Hepatobiliary Neoplasms
Intervention: Genetic: Precise treatment
35 Not yet recruiting HOUSTON - Incidence of Oropharyngeal, Anal and Penile Cancer in Men With Antibodies to Human Papillomavirus (HPV)
Conditions: Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs
Interventions: Procedure: Oropharyngeal Cancer Screening;   Procedure: Ultrasound Scans;   Procedure: Anal Cancer Screening;   Procedure: High-Resolution Anoscopy (HRA);   Procedure: Penile Cancer Screening
36 Recruiting DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium, Tubes and Ovaries
Conditions: Ovarian Neoplasms;   Endometrial Neoplasms;   Endometrial Cancer;   Ovarian Cancer;   Screening;   Safety;   Reduced Mortality;   Reduced Morbidity;   Early Diagnosis
Intervention:
37 Recruiting Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Conditions: Ewing's Family Tumors;   Renal Tumors;   Hepatoblastoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Primary Malignant Brain Neoplasms;   Retinoblastoma;   Medulloblastoma;   Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET);   Atypical Teratoid/Rhabdoid Tumor (AT/RT);   CNS Tumors;   Germ Cell Tumors
Interventions: Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Biological: G-CSF;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Leukapheresis
38 Recruiting Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Conditions: Malignant Neoplasm of Stomach;   Secondary Malignant Neoplasm of Peritoneum;   Secondary Malignant Neoplasm of Other and Unspecified Sites
Intervention: Procedure: HIPEC
39 Not yet recruiting Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery
Conditions: Malignant Neoplasms of Female Genital Organs;   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention: Drug: Bevacizumab
40 Not yet recruiting A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Conditions: Gynecologic Neoplasms;   Epithelial Ovarian Cancer;   Uterine Endometrial Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Pembrolizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years